Dr. Ling Su is currently a Venture Partner in LAV (Lilly Asia Ventures). He has 30 years of experience in pharmaceutical regulatory and clinical development. Early in his career, he worked in the Bureau of Drugs of the Ministry of Health, China (the predecessor of today’s Chinese regulatory agency) and in CDER, US FDA. He joined Merck & Co. in 1996 and subsequently he spent 16 years in various R&D and management positions in multinational pharmaceutical companies, both in US and China. He had been an Epidemiologist/Sr. Epidemiologist in Merck Research Labs (MRL) (US), Medical Director, Merck Sharp & Dohme China, and Senior Regulatory Strategy Director at MRL (US); Pharma Development and Medical Director at Roche (Shanghai); VP for Clinical Research Asia Pacific at Wyeth/Pfizer; and SVP and Head of Pharma Development Greater China at Novartis. In these positions, he has successfully built up pharma clinical development organizations in China, overseen and managed a large number of global Phase I-IV clinical trials in China and in Asia Pacific region, and provided the leadership and strategic direction supporting company’s drug development programs in the region. In 2012-2016, Dr. Su served as a Life Science Strategic Advisor in Sidley Austin LLP, advising pharmaceutical and biotechnology companies on navigating the Chinese regulatory environment, product development strategies and execution, ensuring quality clinical trial operations, and on regulatory policy and advocacy projects. In his current position in LAV, he is also an advisor to a number of LAV portfolio companies.
Dr. Su was a professor in regulatory science in Shenyang Pharmaceutical University (2016-2020). Currently, he continues to be actively engaged in developing and teaching courses in drug development, including as the course director of the annual post-graduate course “Clinical Research Management”, which he has led to develop four years ago. He is a Research Fellow in the Research Center of National Drug Policy＆Ecosystem, China Pharmaceutical University.
He is an inaugural member of the Biotech Expert Advisory Panel of Hong Kong Stock Exchange (HKEX) when the HKEX implemented the new listing rules for biotech companies in April 2018.
In addition, he has been an advisor to the Chinese regulatory agency on numerous projects and has been involved in developing regulations, guidelines and training. He was a Regulatory Consultant to Bill and Melinda Gates Foundation (2012-2016).
Dr. Su was elected the President of Drug Information Association (DIA) in 2012-2013, the first DIA President from Asia region, and served in the Board of Directors of DIA in 2008-2014. He is currently Fellow of DIA and a member of DIA’s Science and Policy Advisory Council.
He received his B.S. in pharmacology from Shanghai Medical University, China, M.S.in drug clinical development and Ph.D. in epidemiology from University of North Carolina at Chapel Hill, USA.
address: A-216, No.56 Dongzhimen Wai Xie St. Chaoyang, Beijing 100027, China
tel: +86 10 6462 0528
address: Room 1502, Building C Poly West Bund Center, No.275, Ruiping Rd, Xuhui Disrict, Shanghai 200232, China